Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased.

European Journal of Cancer & Clinical Oncology
K S TonkinM Bennett

Abstract

Enlargement of tumour masses with a fall or no change in tumour marker levels was noted in eight of 287 patients during chemotherapy for NSGCT at the Charing Cross and Mount Vernon Hospitals between 1977 and 1988. These eight patients had elements of differentiated teratoma in the primary specimen and in five the enlarging masses showed cystic change on CT scan. The increase in tumour mass occurred within 6 months of starting treatment. At surgery, four patients were found to have differentiated teratoma and have been followed for 15 months to 5 years without relapse. Two patients who also had some areas of embryonal carcinoma in the resected specimens had post-operative chemotherapy and are alive disease free at 8 and 24 months respectively. Two patients died: one post-operatively of uncontrolled haemorrhage secondary to aortic rupture and the second of acute myeloid leukaemia following 8 years of intermittent therapy for unresectable differentiated teratoma. The successful outcome in six of these eight patients suggests that enlarging teratomatous masses on chemotherapy can be managed by surgical resection and, when active tumour is present, by the use of post-operative chemotherapy.

Citations

Mar 4, 2000·Toxicology in Vitro : an International Journal Published in Association with BIBRA·A De Vizcaya-RuizM Dobrota
Jul 19, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F AndréC Théodore
Mar 1, 1991·Actas urologicas españolas·P Urruchi FernándezL A Rioja Sanz
Mar 7, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S TangjitgamolC Sheanakul
May 5, 2009·Journal of Neurosurgery. Pediatrics·Doo-Sik KongHyung Jin Shin
Aug 13, 2009·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Vladislav GorbatiyLouis L Pisters
May 31, 2012·Case Reports in Obstetrics and Gynecology·Nirmala KampanAhmad Zailani Hatta Mohd Dali
Aug 21, 2003·European Radiology·Tsutomu InaokaTamio Aburano
Apr 23, 2013·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Kevin ByrdChad A Hamilton
Jan 27, 2015·Journal of Minimally Invasive Gynecology·Naoya ShigetaTadashi Kimura
Mar 12, 2005·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Wuntkal RekhaTongaonkar Hemant
Apr 1, 2011·The Journal of Obstetrics and Gynaecology Research·Satomi KikawaNoriaki Sakuragi
Jul 4, 2009·Taiwanese Journal of Obstetrics & Gynecology·Tsung-Ying HsiehChen-Yang Chou
Dec 19, 2003·The Urologic Clinics of North America·Michael A S JewettJames McKiernan
Sep 7, 2002·The Journal of Obstetrics and Gynaecology Research·Yoshio ItaniKatsutada Hiraoka
May 3, 2005·Obstetrics and Gynecology·Michelle F BenoitJulie L Strickland
Sep 2, 2006·Obstetrics and Gynecology·Livia ZagaméCatherine Lhommé
Jan 17, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Enrica BentivegnaSebastien Gouy
Dec 14, 2005·Journal of Pediatric Hematology/oncology·Paul T JubinskyMelissa Tesher
Apr 14, 2012·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Elizabeth G MorencyTamara Kalir
Feb 1, 1991·British Journal of Urology·G M JefferyG M Mead
Apr 22, 2008·Journal of Pediatric Endocrinology & Metabolism : JPEM·Ebru ArhanSadi Vidinlisan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.